Vascular Biogenics (NASDAQ:VBLT) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Vascular Biogenics (NASDAQ:VBLT – Get Rating) in a report released on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Vascular Biogenics Price Performance

NASDAQ:VBLT remained flat at $0.14 during trading hours on Friday. The company had a trading volume of 1,027,376 shares, compared to its average volume of 10,688,738. The stock has a fifty day simple moving average of $0.15 and a two-hundred day simple moving average of $0.15. Vascular Biogenics has a fifty-two week low of $0.10 and a fifty-two week high of $2.20.

Institutional Trading of Vascular Biogenics

Large investors have recently bought and sold shares of the business. Group One Trading L.P. boosted its stake in Vascular Biogenics by 62.0% in the third quarter. Group One Trading L.P. now owns 293,118 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 112,148 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Vascular Biogenics in the third quarter valued at about $52,000. Telemetry Investments L.L.C. raised its position in Vascular Biogenics by 239.0% in the third quarter. Telemetry Investments L.L.C. now owns 400,000 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 282,000 shares during the last quarter. Envestnet Asset Management Inc. bought a new position in Vascular Biogenics in the first quarter valued at about $64,000. Finally, Two Sigma Investments LP bought a new position in Vascular Biogenics in the third quarter valued at about $66,000. 4.81% of the stock is owned by institutional investors and hedge funds.

About Vascular Biogenics

(Get Rating)

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.